Bio-Thera and Dr. Reddy's expand partnership for BAT2306 (Secukinumab) in Southeast Asia

Bio-Thera (Stock Code: 688177), a science-driven global biopharmaceutical company headquartered in Guangzhou, China, announced that it has entered into a licensing and commercialization agreement with Dr. Reddy's for BAT2306, a biosimilar of Cosentyx® (secukinumab), in the Southeast Asian market.

Under the terms of the agreement, Dr. Reddy's has been granted exclusive distribution and commercialization rights for BAT2306 in Southeast Asian markets including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Thailand. Dr. Reddy's will be responsible for the registration and commercial sales of BAT2306 in these territories, while Bio-Thera will retain responsibility for the development, manufacturing, and commercial supply of BAT2306, for which the Marketing Authorization Application (MAA) has been accepted for review by the National Medical Products Administration (NMPA) in China.

Dr. Reddy's CEO, M.V. Ramana, stated, "This expanded collaboration with Bio-Thera underscores our steadfast commitment to advancing high-efficacy therapies and marks another critical step in our strategy to expand the footprint of biosimilars in emerging markets, thereby enhancing global patient access to advanced treatments."

Bert Thomas, Senior Vice President of Global Business Development at Bio-Thera, commented, "We are delighted to deepen our partnership with Dr. Reddy's in the Southeast Asian market. Introducing high-quality biosimilars at an affordable cost is crucial to improving access to innovative therapies in this region. Dr. Reddy's strong commercial presence and execution capabilities across these markets will be instrumental in maximizing the reach and benefits of our biosimilars to patients."